bodrum escort
antalya escort bayan
beylikduzu escort sirinevler escort beylikduzu escort
anal porno zdarma hot sexy black girls xxx old man and girl



  • Lingani C, Bergeron-Caron C, Stuart J, Fernandez K, Djingarey M. Meningococcal Meningitis Surveillance in the African Meningitis Belt, 2004–2013.Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S410-5.
  • Greenwood B. Editorial: 100 years of epidemic meningitis in West Africa – has anything changed? Trop Med Int Health. 2006 Jun;11(6):773-80.
  • Greenwood B, Stuart JM. A vaccine to prevent epidemic meningitis in Africa. Lancet Infect Dis. 2012 Oct;12(10):738-9.
  • Greenwood B. Meningococcal Meningitis in Africa. Trans R Soc Trop Med Hyg. 1999 Jul-Aug;93(4):341-53.
  • MacNeil J, Medah I, Koussoubé D, Novak R, Cohn A. Increase in Neisseria meningitidis Serogroup W, Burkina Faso, 2012. Emerg Infect Dis. 2014 Mar;20(3):394-9.
  • Morais L, da Glo´ ria Carvalho M, Roca A, Flannery B, Mandomando I. Sequential multiplex PCR for identifying pneumococcal capsular serotypes from south- Saharan African clinical isolates. J Med Microbiol. 2007 Sep;56(Pt 9):1181-4.
  • Kristiansen P, Diomande F, Wei S, Oue´draogo R, Sangare L. Baseline Meningococcal Carriage in Burkina Faso before the Introduction of a Meningococcal Serogroup A Conjugate Vaccine. Clin Vaccine Immunol. 2011 Mar;18(3):435-43.
  • LaForce FM, Ravenscroft N, Djingarey N, Viviani S. Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: A persistent problem with an imminent solution. Vaccine. 2009 Jun 24;27 Suppl 2:B13-9

Vaccine Effectiveness

  • Novak R, Kambou J, Diomandé F, Tarbangdo T, Ouédraogo-Traoré R. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis. 2012; 12: 757–64.
  • Sambo L, Chan M, Davis S, Lake A, Berkley S. A Vaccine Meets Its Promise: Success in Controlling Epidemic Meningitis in Sub-Saharan Africa. Clin Infect Dis. 2015; 61(S5):S387–8.
  • Okwo-Bele JM, LaForce M, Borrow R, Preziosi MP. Documenting the Results of a Successful Partnership: A New Meningococcal Vaccine for Africa. Clin Infect Dis. 2015;61(S5):S389–90.
  • Aguado MT, Jodar L, Granoff D, Rabinovich R, Ceccarini C. From Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine Project. Clin Infect Dis. 2015; 61(S5):S391–5.
  • Tiffay K, Jodar L, Kieny MP, Socquet M, and LaForce FM. The Evolution of the Meningitis Vaccine Project. Clin Infect Dis. 2015;61(S5):S396–403.
  •  Frasch C, Kapre S, Lee C, and Préaud JM. Technical Development of a New Meningococcal Conjugate Vaccine. Clin Infect Dis. 2015;61(S5):S404–9.
  • Idoko O, Diallo A, Sow S, Hodgson A, Akinsola A. Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials. Clin Infect Dis. 2015;61(S5):S416–21.
  • Enwere G, Paranjape G, Kulkarni P, Ginde M, Hartmann K. Safety Monitoring in Group A Meningococcal Conjugate Vaccine Trials: Description,Challenges, and Lessons. Clin Infect Dis. 2015;61(S5):S501–6.
  • Tapia M, Sow S, Cheick Haidara F, Diallo F, Doumbia M. A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians. Clin Infect Dis. 2015; 61(S5):S507–13.
  • Tapia M, Findlow H, Idoko O, Preziosi MP, Kulkarni P. Antibody Persistence 1–5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12–23 Months of Age. Clin Infect Dis. 2015; 61(S5):S514–20.
  • Tang Y, Plikaytis B, Preziosi MP, and Borrow R. Influence of Age on Antibody Response and Persistence Following Immunization With MenAfriVac. Clin Infect Dis. 2015;61(S5):S531–9.
  • Tall H, Yaro S, Kpoda H, Ouangraoua S, Trotter C. Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso. Clin Infect Dis. 2015; 61(S5):S540–6.
  • Borrow R, Tang Y, Yakubu A, Kulkarni P, and LaForce FM. MenAfriVac as an Antitetanus Vaccine. Clin Infect Dis. 2015; 61(S5):S570–7.
  • Djingarey M, Barry R, Bonkoungou M, Tiendrebeogo S, Sebgo R. Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience. Vaccine. 2012 May 30;30 Suppl 2:B40-5
  • LaForce FM, Okwo-Bele JM. Eliminating Epidemic Group A Meningococcal Meningitis In Africa Through A New Vaccine. Health Aff (Millwood). 2011 Jun;30(6):1049-57.
  • Sow S, Okoko, B, Diallo A, Viviani S, Borrow R. Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans. N Engl J Med. 2011; 364:2293-304.
  • Kristiansen P, Diomandé F, Ky Ba A, Sanou I, Ouédraogo AS. Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity. Clin Infect Dis. 2013;56(3):354–63.
  • Xie O, Bolgiano B, Gao F, Lockyer K, Swann C. Characterization of size, structure and purity of serogroup X Neisseria meningitidis polysaccharide, and development of an assay for quantification of human antibodies. Vaccine. 30 (2012) 5812– 5823.
  • Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D. Clinical and Immunologic Risk Factors for Meningococcal C Conjugate Vaccine Failure in the United Kingdom. J Infect Dis. 2006 Dec 15;194(12):1745-52.

Vaccine Implications

  • Martellet L, Sow S, Diallo A, Hodgson A, Kampmann B. Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate Vaccine. Clin Infect Dis. 2015;61(S5):S422–7.
  • Cibrelus L, Lingani C, Fernandez K, Djingarey M, Perea W. Risk Assessment and Meningococcal A Conjugate Vaccine Introduction in Africa: The District Prioritization Tool. Clin Infect Dis. 2015;61(S5):S442–50.
  • Berlier M, Barry R, Shadid J, Sirica C, Brunier A. Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa. Clin Infect Dis. 2015; 61(S5):S451–8.
  • Diomandé F, Djingarey M, Daugla D, Novak R, Kristiansen P. Public Health Impact After the Introduction of PsA-TT: The First 4 Years. Clin Infect Dis. 2015; 61(S5):S467–72.
  • Colombini A, Trotter C, Madrid Y, Karachaliou A, and Preziosi MP. Costs of Neisseria meningitidis Group A Disease and Economic Impact of Vaccination in Burkina Faso. Clin Infect Dis. 2015; 61(S5):S473–82.
  • Basta N, Borrow R, Berthe A, Traoré Eps Dembélé A, Onwuchekwa U. Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali. Clin Infect Dis. 2015; 61(S5):S547–53.
  • Basta N, Borrow R, Berthe A, Onwuchekwa U, Traoré Eps Dembélé A. Higher Tetanus Toxoid Immunity 2 Years After PsA-TT Introduction in Mali. Clin Infect Dis. 2015; 61(S5):S578–85.
  • Chowdhury P, Meier C, Laraway H, Tang Y, Hodgson A. Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali. Clin Infect Dis. 2015;61(S5):S586–93.
  • Karachaliou A, Conlan A,Preziosi MP, and Trotter C. Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt. Clin Infect Dis. 2015; 61(S5):S594–600.
  • Hajjeh R, Privor-Dumm L, Edmond K, O’Loughlin R, Shetty S. Supporting new vaccine introduction decisions: Lessons learned from the Hib Initiative experience. Vaccine. 2010 Oct 8;28(43):7123-9.
  • Colombini A, Badolo O, Gessner B, Jaillard P, Seini E. Costs and impact of meningitis epidemics for the public health system in Burkina Faso. Vaccine. 2011; 19:5474– 80.
  • Greenwood B. Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine. 2013 Mar 1;31(11):1453-7.
  • Ouandaogo C, Yaméogo T, Diomandé F, Sawadogo C, Ouédraogo B. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010. Vaccine. 2012 May 30;30 Suppl 2:B46-51.
  • Basta N, Broome C, Clark T, Greenwood B, Mueller B and Stephens D. Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine. 2013 Mar 1;31(11):1453-7.